Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305669 · ClinicalTrials.gov registry record · Phase 1
GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00305669 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 24 participants.
The verdict
NCT00305669, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Colony-stimulating factors, such as GM-CSF, may help the body build an effective immune response to kill tumor cells. Giving GM-CSF before surgery may be an effective treatment for localized prostate cancer. PURPOSE: This clinical trial is studying how well giving GM-CSF before surgery works in treating patients with localized prostate cancer.
Interventions
- OTHER laboratory biomarker analysis
- OTHER immunohistochemistry staining method
- PROCEDURE conventional surgery
- BIOLOGICAL sargramostim
- OTHER immunological diagnostic method
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-07 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305669
The ClinicalTrials.gov registry entry for NCT00305669 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00305669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00305669 about?
NCT00305669 is a clinical study titled "GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer". RATIONALE: Colony-stimulating factors, such as GM-CSF, may help the body build an effective immune response to kill tumor cells. Giving GM-CSF before surgery may be an effective treatment for localized prostate cancer. PURPOSE: This clinical trial is studying how well giving GM-CSF before surgery w...
What is the current status of trial NCT00305669?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2006-07. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00305669?
The interventions under investigation include: laboratory biomarker analysis (OTHER), immunohistochemistry staining method (OTHER), conventional surgery (PROCEDURE), sargramostim (BIOLOGICAL), immunological diagnostic method (OTHER).
Who is sponsoring clinical trial NCT00305669?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.